TrovaGene has named Antonius Schuh as the company's new chief executive officer (CEO).
Previously Schuh served at Sorrento Therapeutics as chairman and CEO and expanded the company with the production of human antibody libraries using the company’s proprietary platform.
He also served as CEO at AviaraDx and sold it to bioMerieux in 2008, where AviaraDx is continuing to operate under the name bioTheranostics.
At Arcturus Bioscience, Schuh served as CEO and sold Arcturus’ life science business to Molecular Devices and at Sequenom he served as the president and CEO from 2000 to 2005.
TrovaGene chairman Thomas Adams said the company has made efforts to establish the utility of trans-renal nucleic acids in urine as a diagnostic sample in clinical fields as diverse as detection of minimal residual disease in oncology, infectious disease, transplant medicine and prenatal monitoring.
"We are pleased that Schuh joins us to lead the transition of TrovaGene from a research stage organization to a commercial enterprise," Adams said.
TrovaGene CEO Antonius Schuh said he is confident that they can introduce novel diagnostic modalities with significant clinical utility based on trans-renal technology platform.